Back to top
more

Cencora, Inc. (COR)

(Real Time Quote from BATS)

$285.59 USD

285.59
1,105,363

-6.76 (-2.31%)

Updated Aug 6, 2025 12:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (73 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

COR Stock Gains on Q1 Earnings & Revenue Beat & Upbeat '25 Outlook

by Zacks Equity Research

COR's first-quarter fiscal 2025 results showcase a strong segmental performance. The company's sales and earnings guidance for fiscal 2025 looks encouraging.

Zacks Equity Research

Here's What Key Metrics Tell Us About Cencora (COR) Q1 Earnings

by Zacks Equity Research

The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Cencora (COR) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Cencora (COR) delivered earnings and revenue surprises of 6.57% and 4.31%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Premier, Inc. (PINC) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Premier (PINC) delivered earnings and revenue surprises of -6.90% and 1.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Cencora (COR) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Stay Ahead of the Game With Cencora (COR) Q1 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Zacks Equity Research

Cencora to Report Q1 Earnings: Is a Beat Likely for the Stock?

by Zacks Equity Research

COR's fiscal first-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.

Zacks Equity Research

The Zacks Analyst Blog Highlights Amgen, Cencora, Humana and Ardent Health

by Zacks Equity Research

Amgen, Cencora, Humana and Ardent Health are included in this Analyst Blog.

Zacks Equity Research

Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up

by Zacks Equity Research

Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.

Zacks Equity Research

Zimmer Biomet Set to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

ZBH's Hips business is expected to have witnessed growth banking on its suite of navigation solutions in direct anterior stems and surgical impactors.

Zacks Equity Research

Avantor, Inc. (AVTR) Q4 Earnings Preview: What's in the Cards?

by Zacks Equity Research

Avantor (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Labcorp Set to Report Q4 Earnings: What's in Store for the Stock?

by Zacks Equity Research

In the fourth quarter of 2024, LH is likely to have witnessed strong growth in both diagnostics and biopharma laboratory services.

Kaibalya Pravo Dey headshot

4 Healthcare Stocks Poised to Crush Q4 Earnings Estimates

by Kaibalya Pravo Dey

Rising patient volumes, technological advancements, rate hikes and other factors are likely to have benefited healthcare players during Q4. Companies like AMGN, COR, HUM and ARDT are likely to outperform.

Zacks Equity Research

Zacks.com featured highlights include American Express, Pool, Raymond James Financial and Cencora

by Zacks Equity Research

American Express, Pool, Raymond James Financial and Cencora are part of the Zacks Screen of the Week article.

Zacks Equity Research

Edwards Lifesciences Q4 Earnings Set to Benefit From TAVR Growth

by Zacks Equity Research

Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.

Zacks Equity Research

TECH Gears Up to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

In the second quarter, Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and an increase in biotech customers' ordering trends.

Vasundhara Sawalka headshot

4 GARP Stocks That Investors Can Scoop Up for Maximum Returns

by Vasundhara Sawalka

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. AXP, POOL, RJF and COR hold promise.

Zacks Equity Research

Here's Why You Should Add Cencora Stock to Your Portfolio Now

by Zacks Equity Research

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Breast Health Performance Likely to Aid Hologic's Q1 Earnings

by Zacks Equity Research

In the first quarter of fiscal 2025, HOLX is expected to have benefited from expanding breast health offerings.

Zacks Equity Research

Revvity Gears Up for Q4 Earnings: What's in the Offing?

by Zacks Equity Research

RVTY's fourth-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.

Zacks Equity Research

Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.